 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Name:
|
Propentofylline
|
|
Other Names:
|
HWA 285
|
|
FDA Phase:
|
Discontinued
|
|
Role in Alzheimer's Disease:
|
General improvement in mild-moderately demented
Alzheimer's disease patients.
|
|
Pharmacological Role:
|
Adenosine uptake/phosphodiesterase inhibitor (? A
neuroprotective agent).
|
|
Side Effects:
|
Nausea (7% vs. 2% placebo); dizziness (6% vs. 3%); GI pain
(5% vs. 1%); headache (5% vs. 1%).
|
|
Evidence pro its efficacy:
|
A recent, pretty big, double-blinded placebo-controlled
multicenter study supported the use of propentofylline in
Alzheimer's and vascular dementia. The criteria that were
used included activities of daily living and cognitive
skills, both of which were quite statistically
significantly increased in the treated group.
|
|
Evidence con its efficacy:
|
A long term (72-week) PhaseIIIb clinical study yielded
disappointing results, with no treatment differences
between study population treated with propentofylline and
the population treated with placebo.
|
|
Dosage:
|
300 mg per day, three times daily.
|
|
Notes:
|
Development of propentofylline discontinued after
Phase IIIb clinical study. This record was last updated Dec
19, 2008.
|
Frampton M, Harvey RJ, Kirchner V. Propentofylline for
dementia (cochrane review). Cochrane Database Syst Rev.
2003. CD002853. Abstract
Koriyama Y, Yamazaki M, Chiba K, Mohri T. Evaluation of
neurotoxicity of alzheimer's amyloid beta protein (beta42)
in cultured hippocampal cells and its prevention by
propentofylline. Jpn J Pharmacol. 2000 Apr;82(4):301-6. Abstract
Ringheim GE. Glial modulating and neurotrophic properties
of propentofylline and its application to Alzheimer's
disease and vascular dementia. Ann N Y Acad Sci. 2000
Apr;903:529-34. Medline Record
Wirtz-Brugger F, Giovanni A. Guanosine 3',5'-cyclic
monophosphate mediated inhibition of cell death induced by
nerve growth factor withdrawal and beta-amyloid:
protective effects of propentofylline.
Neuroscience. 2000;99(4):737-50. Abstract
Kittner B. Clinical trials of propentofylline in vascular
dementia. European/Canadian Propentofylline Study Group.
Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13 Suppl 3:S166-
71. Abstract
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Participate in Research
See a list of research studies, projects, and clinical trials in search of research participants.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
